Advertisement

Drug-Drug Interactions and Psychiatric Medication

  • Laurence J. Kinsella
Chapter

Abstract

How many of us in clinical practice have heard the question: “Doctor, will this drug interact with any of my other medications?” This common question has been challenging to answer, often leading to using laborious drug interaction computer programs, smartphone-based programs, or a call to the pharmacist. The purpose of this chapter is to help address this question, assess the likelihood of a drug-drug interaction, and advise the patient on what to expect should they experience an adverse drug effect.

References

  1. 1.
    Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diag Ther. 2013;17(3):165–84.  https://doi.org/10.1007/s40291-013-0028-5.CrossRefGoogle Scholar
  2. 2.
    Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391–9.PubMedGoogle Scholar
  3. 3.
    Sharma A, Pibarot P, Pilote S, et al. Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction. J Clin Pharmacol. 2010;50(2):214–25.  https://doi.org/10.1177/0091270009340417.CrossRefPubMedGoogle Scholar
  4. 4.
    Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014;21(8):879–85.  https://doi.org/10.1111/acem.12431.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chang K-L, Weitzel K, Schmidt S. Pharmacogenetics: using genetic information to guide drug therapy. Am Fam Physician. 2015;92(7):588–94.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Lerner B. A case that shook medicine. Washington Post. http://www.washingtonpost.com/wp-dyn/content/article/2006/11/24/AR2006112400985.html. Published November 28, 2006.
  7. 7.
    Hoffman J. Judge sets aside use of cocaine as part of verdict in zion case. New York Times. http://query.nytimes.com/gst/fullpage.html?res=990CE6DE1F38F931A35756C0A963958260&sec=&spon=&pagewanted=2. Published 1995.
  8. 8.
    Asch DA, Parker RM. The libby zion case. N Engl J Med 1988;318:771–75.CrossRefPubMedGoogle Scholar
  9. 9.
    Nasca TJ, Day SH, Amis ESJ. The new recommendations on duty hours from the ACGME Task Force. N Engl J Med. 2010;363(2):e3.  https://doi.org/10.1056/NEJMsb1005800.CrossRefPubMedGoogle Scholar
  10. 10.
    Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–16.  https://doi.org/10.1001/jama.289.9.1107.CrossRefPubMedGoogle Scholar
  11. 11.
    Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.  https://doi.org/10.1136/bmj.329.7456.15.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Burroughs TE, Waterman AD, Gallagher TH, et al. Patient concerns about medical errors in emergency departments. Acad Emerg Med. 2005;12(1):57–64.  https://doi.org/10.1111/j.1553-2712.2005.tb01480.x.CrossRefPubMedGoogle Scholar
  13. 13.
    McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2016;36(9):1331–6.  https://doi.org/10.1345/aph.1A333.CrossRefGoogle Scholar
  14. 14.
    Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit. Drug Saf. 2008;31(6):545–56.  https://doi.org/10.2165/00002018-200831060-00009.CrossRefPubMedGoogle Scholar
  15. 15.
    Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16(6):641–51.  https://doi.org/10.1002/pds.1351.CrossRefPubMedGoogle Scholar
  16. 16.
    Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. JAMA. 1995;274(1):35–43.  https://doi.org/10.1001/jama.1995.03530010049034.CrossRefPubMedGoogle Scholar
  17. 17.
    Marino A, Capogrosso-Sansone A, Tuccori M, et al. Expected and actual adverse drug-drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study. Expert Opin Drug Saf. 2016;15(sup2):45–50.  https://doi.org/10.1080/14740338.2016.1221400.CrossRefPubMedGoogle Scholar
  18. 18.
    Phansalkar S, van der Sijs H, Tucker AD, et al. Drug–drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. J Am Med Inform Assoc. 2013;20(3):489–93.  https://doi.org/10.1136/amiajnl-2012-001089.CrossRefPubMedGoogle Scholar
  19. 19.
    Nebeker JR, Hoffman JM, Weir CR, Bennett CL, Hurdle JF. High rates of adverse drug events in a highly computerized hospital. Arch Intern Med. 2005;165(10):1111–6.  https://doi.org/10.1001/archinte.165.10.1111.CrossRefPubMedGoogle Scholar
  20. 20.
    Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007;167(16):1752–9.  https://doi.org/10.1001/archinte.167.16.1752.CrossRefPubMedGoogle Scholar
  21. 21.
    Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–12.  https://doi.org/10.1056/NEJMsa1103053.CrossRefPubMedGoogle Scholar
  22. 22.
    By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.  https://doi.org/10.1111/jgs.13702.CrossRefGoogle Scholar
  23. 23.
    Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147(11):755–65.  https://doi.org/10.7326/0003-4819-147-11-200712040-00006.CrossRefPubMedGoogle Scholar
  24. 24.
    Patterns of medication use in the United States. http://www.bu.edu/slone/files/2012/11/SloneSurveyReport2006.pdf. Published 2006. Accessed 4 Sept 2017.
  25. 25.
    Leone R, Magro L, Moretti U, et al. Identifying adverse drug reactions associated with drug-drug interactions. Drug Saf. 2010;33(8):667–75.  https://doi.org/10.2165/11534400-000000000-00000.CrossRefPubMedGoogle Scholar
  26. 26.
    Sirot EJ, van der Velden JW, Rentsch K, Eap CB, Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf. 2006;29(9):735–68.  https://doi.org/10.2165/00002018-200629090-00001.CrossRefGoogle Scholar
  27. 27.
    Pedavally S, Fugate JE, Rabinstein AA. Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications. Neurocrit Care. 2014;21(1):108–13.  https://doi.org/10.1007/s12028-013-9914-2.CrossRefPubMedGoogle Scholar
  28. 28.
    Jeffrey R, Strawn MD, Paul E, Keck MD Jr, Stanley N, Caroff MD. Neuroleptic malignant syndrome. Am J Psychiatr. 2007.  https://doi.org/10.1176/ajp.2007.164.issue-6;page:string:Article/Chapter.
  29. 29.
    Christodoulou C, Kalaitzi C. Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review. J Psychopharmacol (Oxford). 2005;19(3):307–11.  https://doi.org/10.1177/0269881105051543.CrossRefGoogle Scholar
  30. 30.
    Bookwalter T, Gitlin M. Gabapentin-induced neurologic toxicities. Pharmacother J Hum Pharmacol Drug Ther. 2005;25(12):1817–9.  https://doi.org/10.1592/phco.2005.25.12.1817. CrossRefGoogle Scholar
  31. 31.
    Lee C-P, Chen P-J, Chang C-M. Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia. Acta Neuropsychiatr. 2015;27(6):380–5.  https://doi.org/10.1017/neu.2015.29.CrossRefPubMedGoogle Scholar
  32. 32.
    Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087–91.  https://doi.org/10.1111/j.1528-1167.2008.01719.x.CrossRefPubMedGoogle Scholar
  33. 33.
    Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a poison control center system. J Med Toxicol. 2007;3(1):15–9.  https://doi.org/10.1007/BF03161033.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153(6):891–9.  https://doi.org/10.1016/j.ahj.2007.01.040.CrossRefPubMedGoogle Scholar
  35. 35.
    Sheikh HU, Mathew PG. Reversible cerebral vasoconstriction syndrome: updates and new perspectives. Curr Pain Headache Rep. 2014;18(5):414.  https://doi.org/10.1007/s11916-014-0414-7. CrossRefPubMedGoogle Scholar
  36. 36.
    Wong VSS, Singh H, Verro P. Posterior reversible encephalopathy syndrome in the context of phentermine use resulting in intracranial hemorrhage. Neurologist. 2011;17(2):111–3.  https://doi.org/10.1097/NRL.0b013e31820a9ddc.CrossRefPubMedGoogle Scholar
  37. 37.
    Hung T-Y, Seow V-K, Chong C-F, Wang T-L, Chen C-C. Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia. Emerg Med J. 2008;25(3):178–9.  https://doi.org/10.1136/emj.2007.053470.CrossRefPubMedGoogle Scholar
  38. 38.
    Zand L, McKian KP, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am J Med. 2010;123(4):367–73.  https://doi.org/10.1016/j.amjmed.2009.09.030.CrossRefPubMedGoogle Scholar
  39. 39.
    Chau V, Prasad S, Stewart D, Heckman G. Creutzfeldt–Jakob disease-like syndrome induced by gabapentin toxicity. Age Res. 2010;1(1):3.  https://doi.org/10.4081/ar.2010.e3.CrossRefGoogle Scholar
  40. 40.
    Babiy M, Stubblefield MD, Herklotz M, Hand M. Asterixis related to gabapentin as a cause of falls. Am J Phys Med Rehabil. 2005;84(2):136–40.  https://doi.org/10.1097/01.PHM.0000151943.06257.64.CrossRefPubMedGoogle Scholar
  41. 41.
    Clark SL, Rabinstein AA, Hocker SE. Disabling asterixis induced by gabapentin. J Med Case. 2015;6(7):285–6.  https://doi.org/10.14740/jmc.v6i7.2143. CrossRefGoogle Scholar
  42. 42.
    Sternbach H. The serotonin syndrome. Am J Psychiatr. 1991;148:705–16.CrossRefPubMedGoogle Scholar
  43. 43.
    Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2009;352(11):1112–20.  https://doi.org/10.1056/NEJMra041867.CrossRefGoogle Scholar
  44. 44.
    Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology. 1995;45(2):219–23.  https://doi.org/10.1212/WNL.45.2.219.CrossRefPubMedGoogle Scholar
  45. 45.
    Evans RW, Tepper SJ, Shapiro RE, Sun Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache J Head Face Pain. 2010;50(6):1089–99.  https://doi.org/10.1111/j.1526-4610.2010.01691.x.CrossRefGoogle Scholar
  46. 46.
    Watson WA, Litovitz TL, Rodgers GC, Klein-Schwartz W, Youniss J, Rose SR, Borys D, May ME. 2002 annual report of the American Association of poison control centers toxic exposure surveillance system. Am J Emerg Med. 2003;21(5):353–421.CrossRefPubMedGoogle Scholar
  47. 47.
    Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49(448):871–4.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003 Sep 1;96(9):635–42.CrossRefPubMedGoogle Scholar
  49. 49.
    Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52(1):1–8.  https://doi.org/10.1007/s40262-012-0018-5.CrossRefPubMedGoogle Scholar
  50. 50.
    Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Therap. 2002;71(3):115–21.  https://doi.org/10.1067/mcp.2002.121829.CrossRefGoogle Scholar
  51. 51.
    Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2009;351(27):2827–31.  https://doi.org/10.1056/NEJMoa041888.CrossRefGoogle Scholar
  52. 52.
    Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211–21.  https://doi.org/10.1056/NEJMra032424.CrossRefPubMedGoogle Scholar
  53. 53.
    Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2(6):347–56.  https://doi.org/10.1016/S1474-4422(03)00409-5.CrossRefPubMedGoogle Scholar
  54. 54.
    Xu C, Li CY-T, Kong A-NT. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005;28(3):249–68.  https://doi.org/10.1007/BF02977789.CrossRefPubMedGoogle Scholar
  55. 55.
    Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12(8):927–41.  https://doi.org/10.1634/theoncologist.12-8-927.CrossRefPubMedGoogle Scholar
  56. 56.
    Werner D, Wuttke H, Fromm MF, et al. Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol. 2004;94(10):1319–21.  https://doi.org/10.1016/j.amjcard.2004.07.125.CrossRefPubMedGoogle Scholar
  57. 57.
    Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Therap. 2002;72(4):429–37.  https://doi.org/10.1067/mcp.2002.127111.CrossRefGoogle Scholar
  58. 58.
    Weinshilboum R. Inheritance and drug response. N Engl J Med. 2009;348(6):529–37.  https://doi.org/10.1056/NEJMra020021. CrossRefGoogle Scholar
  59. 59.
    Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286(18):2270–9.  https://doi.org/10.1001/jama.286.18.2270.CrossRefPubMedGoogle Scholar
  60. 60.
    de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66(1):15–27.CrossRefPubMedGoogle Scholar
  61. 61.
    Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol. 2000;56(8):585–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Zevin S, Benowitz NL. Drug interactions with tobacco smoking. Clin Pharmacokinet. 1999;36(6):425–38.  https://doi.org/10.2165/00003088-199936060-00004.CrossRefPubMedGoogle Scholar
  63. 63.
    Huang SM, Temple R. Is this the drug or dose for you?: impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther. 2008;84(3):287–94.  https://doi.org/10.1038/clpt.2008.144.CrossRefPubMedGoogle Scholar
  64. 64.
    Hartmann AM, Giegling I, Genius J, Schäfer M, Bondy B, Möller HJ, Rujescu D. A study on pharmacogenetics of haloperidol treatment. Pharmacopsychiatry. 2007 Sep;40(05):A078.Google Scholar
  65. 65.
    Šimić I, Potočnjak I, Kraljičković I, et al. CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms. 2016 Pharmacogenomics;17(13):1385–1389. doi: https://doi.org/10.2217/pgs-2016-0069. http://dxdoiorgezpsluedu/102217/pgs-2016-0069CrossRefPubMedGoogle Scholar
  66. 66.
    Bressler R. Grapefruit juice and prescription drug interactions. Geriatrics. 2006;61:12–18.Google Scholar
  67. 67.
    Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Therap. 2005;77(5):415–26.  https://doi.org/10.1016/j.clpt.2005.01.009.CrossRefGoogle Scholar
  68. 68.
    Fosnight SM, Holder CM, Allen KR, Hazelett S. A strategy to decrease the use of risky drugs in the elderly. Cleve Clin J Med. 2004;71(7):561–8.CrossRefPubMedGoogle Scholar
  69. 69.
    Schoretsanitis G, Haen E, Gründer G, et al. Pharmacokinetic drug-drug interactions of mood stabilizers and risperidone in patients under combined treatment. J Clin Psychopharmacol. 2016;36(6):554–61.  https://doi.org/10.1097/JCP.0000000000000601.CrossRefPubMedGoogle Scholar
  70. 70.
    Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care. 2011;26(1):104.e1–6.  https://doi.org/10.1016/j.jcrc.2010.04.014.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologySSM Neuroscience InstituteSt. LouisUSA
  2. 2.Department of NeurologySt. Louis University School of MedicineSt. LouisUSA

Personalised recommendations